Medara was founded in January 2025 and aims to improve early breast cancer detection using cutting-edge AI. The company focuses on predicting short-term cancer risk in high-risk patients with negative screenings. Built on research from the Sabuncu Lab at Cornell Tech and Weill Cornell Medicine, Medara leverages advanced imaging, machine learning, and biomedical data to address missed diagnoses and false positives in current screening methods.